Immunic Inc. (IMUX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 4, 2022 6:30 AM EDTInitial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter
Unblinded Safety Data from the Single and Multiple Ascending Dose Parts of Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Expected in the Third Quarter
$88.1 Million in Cash and Cash Equivalents Expected to Fund Immunic Into the Fourth Quarter of 2023
Webcast to be Held Today, August 4, 2022, at 8:00 am ET
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq:... More
